Dyslipidaemia

4 trials 1 recruiting MedDRA PT
4 Registered trials
1 Recruiting
4 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
C Cardiology (ATC C) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Statin 1 substance
Phase III: 1 Phase II/III: 1 Phase II: 1 Other: 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

1 trial
  • Novartis Pharma AG Commercial
    IMP not specified
    2025-521670-34-00 5 countries 2026 n=135
    Recruiting

Phase II/III

1 trial
  • Semmelweis University Academic
    ROSUVASTATIN
    2025-522868-32-00 1 country n=140
    Pending

Phase II

1 trial
  • AstraZeneca AB Commercial
    1-[6-[[(1S,3S)-3-[[5-(DIFLUOROMETHOXY)PYRIMIDIN-2-YL]AMINO]CYCLOPENTYL]AMINO]PYRIDIN-3-YL]PYRIDIN-2-ONE
    2023-506197-12-00 5 countries 2024 n=209
    Ended

Other

1 trial
  • Laboratorios Alter S.A. Commercial
    IMP not specified
    2026-525230-27-00 1 country 2026 n=36
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Laboratorios Alter S.A. Commercial 1 Other 0
AstraZeneca AB Commercial 1 Phase II 0
Novartis Pharma AG Commercial 1 Phase III 1
Semmelweis University Academic 1 Phase II/III 0
New trials by year
2024
1
2026
2
← All indication landscapes